Tim R Cressey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6274453/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, The, 2022, 399, 629-655.	13.7	4,915
2	Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. New England Journal of Medicine, 2018, 378, 911-923.	27.0	226
3	Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 245-252.	2.1	68
4	Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. New England Journal of Medicine, 2021, 385, 2531-2543.	27.0	57
5	Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infection, Genetics and Evolution, 2007, 7, 333-342.	2.3	56
6	Raltegravir Pharmacokinetics During Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 375-381.	2.1	56
7	Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Archives of Disease in Childhood, 2020, 105, 26-31.	1.9	56
8	Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Medicine, 2015, 16, 502-511.	2.2	50
9	Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 72-77.	2.1	50
10	Infant Growth Outcomes After Maternal Tenofovir Disoproxil Fumarate Use During Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 374-381.	2.1	49
11	Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. Aids, 2005, 19, 1495-1499.	2.2	45
12	Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 33-41.	2.1	41
13	Response to planned treatment interruptions in HIV infection varies across childhood. Aids, 2010, 24, 231-241.	2.2	38
14	Pharmacokinetic Optimization of Antiretroviral Therapy in Pregnancy. Clinical Pharmacokinetics, 2012, 51, 639-659.	3.5	38
15	Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 289-296.	2.1	38
16	Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings. Aids, 2020, 34, 255-260.	2.2	38
17	Predictors of 5-Year Mortality in HIV-Infected Adults Starting Highly Active Antiretroviral Therapy in Thailand. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 91-98.	2.1	36
18	Plasma efavirenz concentrations and the association with <i>CYP2B6</i> -516 G >T polymorphism in HIV-infected Thai children. Antiviral Therapy, 2009, 14, 315-320.	1.0	36

#	Article	IF	CITATIONS
19	Pharmacokinetics of an Increased Atazanavir Dose With and Without Tenofovir During the Third Trimester of Pregnancy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 59-66.	2.1	35
20	Switching HIV Treatment in Adults Based on CD4 Count Versus Viral Load Monitoring: A Randomized, Non-Inferiority Trial in Thailand. PLoS Medicine, 2013, 10, e1001494.	8.4	35
21	Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIVâ€1 infected Thai adults. British Journal of Clinical Pharmacology, 2012, 74, 1005-1012.	2.4	34
22	Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 283-8.	2.1	32
23	Development of a one-step immunochromatographic strip test for the rapid detection of nevirapine (NVP), a commonly used antiretroviral drug for the treatment of HIV/AIDS. Talanta, 2007, 71, 462-470.	5.5	31
24	Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antiviral Therapy, 2011, 16, 1287-1295.	1.0	31
25	Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. Journal of Antimicrobial Chemotherapy, 2009, 64, 1265-1273.	3.0	29
26	Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infectious Diseases, 2016, 16, 393.	2.9	29
27	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clinical Pharmacology and Therapeutics, 2021, 110, 36-48.	4.7	29
28	The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. PLoS ONE, 2013, 8, e76582.	2.5	29
29	A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and Nevirapine. Pediatric Infectious Disease Journal, 2010, 29, 940-944.	2.0	28
30	Efficacy and Safety of 1â€Month Postpartum Zidovudineâ€Didanosine to Prevent HIVâ€Resistance Mutations after Intrapartum Singleâ€Dose Nevirapine. Clinical Infectious Diseases, 2010, 50, 898-908.	5.8	28
31	Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. Lancet HIV,the, 2019, 6, e623-e631.	4.7	27
32	Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antiviral Therapy, 2010, 15, 297-305.	1.0	26
33	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clinical Infectious Diseases, 2017, 64, 1597-1603.	5.8	26
34	ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infectious Diseases, 2021, 21, 5.	2.9	26
35	Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability. Journal of Antimicrobial Chemotherapy, 2005, 55, 1041-1044.	3.0	25
36	Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. Aids, 2010, 24, 2193-2200.	2.2	25

#	Article	IF	CITATIONS
37	Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. Aids, 2013, 27, 579-589.	2.2	24
38	Urine Tenofovir Concentrations Correlate With Plasma and Relate to Tenofovir Disoproxil Fumarate Adherence: A Randomized, Directly Observed Pharmacokinetic Trial (TARGET Study). Clinical Infectious Diseases, 2020, 70, 2143-2151.	5.8	24
39	Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics, 2012, 13, 1501-1522.	1.3	23
40	Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor–Based Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 61, 95-101.	5.8	23
41	Efficacy, Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in Virologic-Suppressed HIV-infected Children Using Weight-Band Dosing. Pediatric Infectious Disease Journal, 2015, 34, 392-397.	2.0	23
42	Youthâ€friendly services and a mobile phone application to promote adherence to preâ€exposure prophylaxis among adolescent men who have sex with men and transgender women atâ€risk for HIV in Thailand: a randomized control trial. Journal of the International AIDS Society, 2020, 23, e25564.	3.0	23
43	Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antiviral Therapy, 2009, 14, 315-20.	1.0	23
44	Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience. Antimicrobial Agents and Chemotherapy, 2012, 56, 5374-5380.	3.2	21
45	New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 453-459.	2.1	20
46	A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study. BMC Infectious Diseases, 2017, 17, 496.	2.9	20
47	Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. European Journal of Cancer, 2002, 38, 586-593.	2.8	19
48	A Comparison of 3 Regimens to Prevent Nevirapine Resistance Mutations in HIV-Infected Pregnant Women Receiving a Single Intrapartum Dose of Nevirapine. Clinical Infectious Diseases, 2012, 54, 285-293.	5.8	19
49	The role of formulation on the pharmacokinetics of antiretroviral drugs. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1019-1037.	3.3	19
50	Point-of-care and Near Real-time Testing for Antiretroviral Adherence Monitoring to HIV Treatment and Prevention. Current HIV/AIDS Reports, 2020, 17, 487-498.	3.1	19
51	Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. Clinical Infectious Diseases, 2019, 69, 144-146.	5.8	18
52	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverseâ€Iranscriptase Inhibitors in HIV Type 1–Infected Children. Clinical Infectious Diseases, 2008, 46, 1601-1608.	5.8	16
53	Reduced indinavir exposure during pregnancy. British Journal of Clinical Pharmacology, 2013, 76, 475-483.	2.4	16
54	Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. Clinical Pharmacokinetics, 2020, 59, 1185-1194.	3.5	16

#	Article	IF	CITATIONS
55	Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, 2020, 59, 1433-1450.	3.5	16
56	Efavirenz pharmacokinetics during pregnancy and infant washout. Antiviral Therapy, 2018, 24, 95-103.	1.0	15
57	Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. PLoS ONE, 2018, 13, e0196239.	2.5	15
58	Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1–2 trial. Lancet HIV,the, 2022, 9, e332-e340.	4.7	15
59	Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 347-361.	3.3	14
60	Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol. Clinical Infectious Diseases, 2017, 65, 982-989.	5.8	14
61	Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Review of Clinical Pharmacology, 2018, 11, 83-93.	3.1	14
62	Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	14
63	Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clinical Pharmacokinetics, 2021, 60, 795-809.	3.5	14
64	Intensive Pharmacokinetics of Zidovudine 200 mg Twice Daily in HIV-1-Infected Patients Weighing Less Than 60 kg on Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 387-389.	2.1	13
65	Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults. Malaria Journal, 2015, 14, 400.	2.3	13
66	Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand. Aids, 2015, 29, 2497-2507.	2.2	13
67	Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 448-458.	8.1	13
68	Developmental Pharmacokinetic Changes of Lamivudine in Infants and Children. Journal of Clinical Pharmacology, 2012, 52, 1824-1832.	2.0	12
69	Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment. Clinical Infectious Diseases, 2015, 61, 633-639.	5.8	12
70	Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 554-560.	2.1	12
71	Recommended First-Line Antiretroviral Therapy Regimens and Risk of Diabetes Mellitus in HIV-Infected Adults in Resource-Limited Settings. Open Forum Infectious Diseases, 2019, 6, ofz298.	0.9	12
72	EFFICACY AND PLASMA CONCENTRATIONS OF INDINAVIR WHEN BOOSTED WITH RITONAVIR IN HUMAN IMMUNODEFICIENCY VIRUS–INFECTED THAI CHILDREN. Pediatric Infectious Disease Journal, 2007, 26, 86-88.	2.0	11

#	Article	IF	CITATIONS
73	Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV. Therapeutic Drug Monitoring, 2019, 41, 431-443.	2.0	11
74	Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	11
75	Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV. PLoS ONE, 2015, 10, e0126647.	2.5	11
76	No Relationship Between Drug Transporter Genetic Variants and Tenofovir Plasma Concentrations or Changes in Glomerular Filtration Rate in HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e56-e59.	2.1	10
77	Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1383-1390.	1.4	10
78	Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. Journal of Antimicrobial Chemotherapy, 2015, 70, 217-224.	3.0	10
79	Incidence and clinical outcomes of diabetes mellitus in HIV-infected adults in Thailand: a retrospective cohort study. BMC Public Health, 2018, 18, 1079.	2.9	10
80	Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate. International Journal of Infectious Diseases, 2020, 97, 365-370.	3.3	10
81	Single Dose Abacavir Pharmacokinetics and Safety in Neonates Exposed to Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 2032-2034.	5.8	10
82	Advancing the prevention and treatment of HIV in children: priorities for research and development. Lancet HIV,the, 2022, 9, e658-e666.	4.7	10
83	Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption. Aids, 2016, 30, 1075-1081.	2.2	9
84	Brief Report: AIDS-Defining Events and Deaths in HIV-Infected Children and Adolescents on Antiretrovirals: A 14-Year Study in Thailand. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 17-22.	2.1	9
85	Semi-quantification of HIV-1 protease inhibitor concentrations in clinical samples of HIV-infected patients using a gold nanoparticle-based immunochromatographic assay. Analytica Chimica Acta, 2019, 1071, 86-97.	5.4	9
86	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. Open Forum Infectious Diseases, 2021, 8, ofab200.	0.9	9
87	A Mobile Phone App to Support Adherence to Daily HIV Pre-exposure Prophylaxis Engagement Among Young Men Who Have Sex With Men and Transgender Women Aged 15 to 19 Years in Thailand: Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2022, 10, e25561.	3.7	9
88	Pharmacokinetics of Pediatric Lopinavir/Ritonavir Tablets in Children When Administered Twice Daily According to FDA Weight Bands. Pediatric Infectious Disease Journal, 2014, 33, 301-305.	2.0	8
89	Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults. Journal of the Pediatric Infectious Diseases Society, 2016, 5, 131-137.	1.3	8
90	A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatric Infectious Disease Journal, 2018, 37, e29-e35.	2.0	8

#	Article	IF	CITATIONS
91	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy, 2019, 74, 1348-1356.	3.0	8
92	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. The Lancet Child and Adolescent Health, 2022, 6, 9-10.	5.6	8
93	Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 324-331.	2.1	8
94	Immunochromatographic Strip Test for Rapid Detection of Nevirapine in Plasma Samples from Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy, 2007, 51, 3361-3363.	3.2	7
95	Comparison of the TaqMan and LightCycler systems in evaluation of CYP2B6 516G>T polymorphism. Molecular and Cellular Probes, 2007, 21, 408-411.	2.1	7
96	Pharmacokinetics of Nevirapine in HIV and Tuberculosis–coinfected Children Receiving Antiretroviral Fixed-dose Combination Tablets While Receiving Rifampicin-containing Tuberculosis Treatment and After Rifampicin Discontinuation. Pediatric Infectious Disease Journal, 2012, 31, 389-391.	2.0	7
97	Does pregnancy affect the pharmacokinetics of efavirenz?. Aids, 2014, 28, 1542-1543.	2.2	7
98	Efavirenz Concentrations and Probability of HIV Replication in Children. Pediatric Infectious Disease Journal, 2015, 34, 1214-1217.	2.0	7
99	Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S40-S48.	2.1	7
100	Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations. Pediatric Infectious Disease Journal, 2021, 40, 1081-1086.	2.0	7
101	Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes. BMJ Open, 2021, 11, e050116.	1.9	7
102	Early Postpartum Pharmacokinetics of Lopinavir Initiated Intrapartum in Thai Women. Antimicrobial Agents and Chemotherapy, 2009, 53, 2189-2191.	3.2	6
103	Adherence to Antiretroviral Therapy and Acceptability of Planned Treatment Interruptions in HIV-Infected Children. AIDS and Behavior, 2013, 17, 193-202.	2.7	6
104	Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. Pediatric Infectious Disease Journal, 2016, 35, e271-e274.	2.0	6
105	Expedient screening for HIV-1 protease inhibitors using a simplified immunochromatographic assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1021, 153-158.	2.3	6
106	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Âmg in Pregnant Women. Clinical Pharmacokinetics, 2018, 57, 1421-1433.	3.5	6
107	Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV,the, 2022, 9, e24-e31.	4.7	6
108	Influence of Body Weight on Achieving Indinavir Concentrations Within Its Therapeutic Window in HIV-Infected Thai Patients Receiving Indinavir Boosted With Ritonavir. Therapeutic Drug Monitoring, 2011, 33, 25-31.	2.0	5

#	Article	IF	CITATIONS
109	Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations. Virology Journal, 2021, 18, 77.	3.4	5
110	What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. Lancet HIV,the, 2022, 9, e649-e657.	4.7	5
111	Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 490-495.	3.0	4
112	Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy. Journal of the Pediatric Infectious Diseases Society, 2017, 6, 161-167.	1.3	4
113	Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. Pediatric Infectious Disease Journal, 2019, 38, 1045-1050.	2.0	4
114	Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarateâ€Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. Journal of Clinical Pharmacology, 2021, 61, 388-393.	2.0	4
115	Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir. Journal of Antimicrobial Chemotherapy, 2012, 67, 2927-2931.	3.0	3
116	Pharmacological Assessment of Efavirenz Weight-Band Dosing Recommendations in HIV-Infected Thai Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e27-e29.	2.1	3
117	Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 313-322.	2.1	3
118	Drug–drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment. Journal of Antimicrobial Chemotherapy, 2021, 76, 1041-1045.	3.0	3
119	Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Medical Research Methodology, 2022, 22, 49.	3.1	3
120	Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children. HIV Medicine, 2014, 15, 511-512.	2.2	2
121	Contribution of Different Antiretroviral Regimens Containing Zidovudine, Lamivudine and Ritonavir-Boosted Lopinavir on HIV Viral Load Reduction during Pregnancy. Antiviral Therapy, 2016, 21, 435-440.	1.0	2
122	Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. Journal of Virus Eradication, 2015, 1, 185-191.	0.5	2
123	Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults. Pediatric Infectious Disease Journal, 2016, 35, 1333-1335.	2.0	2
124	Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis. Pediatric Infectious Disease Journal, 2019, 38, 152-156.	2.0	2
125	Longâ€ŧerm clinical, virological and immunological outcomes following planned treatment interruption in HIVâ€infected children. HIV Medicine, 2021, 22, 172-184. 	2.2	2
126	Lack of Association between Adverse Pregnancy Outcomes and Zika Antibodies among Pregnant Women in Thailand between 1997 and 2015. Viruses, 2021, 13, 1423.	3.3	2

#	Article	IF	CITATIONS
127	Pharmacogenomics and the prevention of mother-to-child transmission of HIV. Pharmacogenomics, 2010, 11, 1-4.	1.3	1
128	Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. Antiviral Therapy, 2018, 23, 259-265.	1.0	1
129	Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Obstetrical and Gynecological Survey, 2018, 73, 443-445.	0.4	1
130	Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children. PLoS ONE, 2019, 14, e0216868.	2.5	1
131	Point-of-care semi-quantitative test for adherence to tenofovir alafenamide or tenofovir disoproxil fumarate. Journal of Antimicrobial Chemotherapy, 2022, 77, 996-999.	3.0	1
132	A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenzâ€Based Regimens. Journal of Clinical Pharmacology, 2016, 56, 1076-1083.	2.0	0
133	Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults: Table 1 Journal of the Pediatric Infectious Diseases Society, 2017, 6, piw017.	1.3	0
134	Serum Theophylline Concentrations in very Preterm Neonates Receiving Intravenous Aminophylline for Apnea. Siriraj Medical Journal, 2021, 73, 526-531.	0.3	0
135	Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. Journal of Virus Eradication, 2015, 1, 185-91.	0.5	0